

# ZOGENIX

## Zogenix Announces 2011 Second Quarter Conference Call and Webcast

August 2, 2011

**Earnings Call Scheduled for August 10, 2011 at 4:30 p.m. ET**

SAN DIEGO, Aug 2, 2011 (GlobeNewswire via COMTEX) --

Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the second quarter ended June 30, 2011, after the market closes on Wednesday, August 10, 2011, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results, as well as provide an update on other company business matters.

To access the live webcast please visit the Investor Relations website at [ir.zogenix.com](http://ir.zogenix.com), and to participate, please dial 800-638-5439 (U.S.) or 617-614-3945 (International); participant passcode: 55963914.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President and Chief Operating Officer Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning August 10, 2011 at 8:30 p.m. ET (5:30 p.m. PT) until September 10, 2011, by dialing 888-286-8010 (U.S.) or 617-801-6888 (International); passcode: 79535694. A replay of the webcast will also be accessible on the Investor Relations website for one month, through September 10, 2011.

### About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zohydro(TM) (hydrocodone bitartrate), is a novel, oral, single-entity extended-release capsule formulation currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro product candidate, Relday(TM), is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia and bipolar I disorder. Zogenix expects to begin clinical studies of Relday in early 2012.

For additional information, please visit [www.zogenix.com](http://www.zogenix.com).

SUMAVEL(R), DosePro(R), Relday(TM) and Zohydro(TM) are trademarks of Zogenix, Inc.

This news release was distributed by GlobeNewswire, [www.globenewswire.com](http://www.globenewswire.com)

SOURCE: Zogenix

### CONTACT: INVESTORS:

Zack Kubow  
The Ruth Group  
646.536.7020  
[zkubow@theruthgroup.com](mailto:zkubow@theruthgroup.com)

### MEDIA:

Victoria Aguiar  
The Ruth Group  
646.536.7013  
[vaguiar@theruthgroup.com](mailto:vaguiar@theruthgroup.com)